Additional Proxy Soliciting Materials (definitive) (defa14a)
May 21 2020 - 08:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section
14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed
by the Registrant x
|
|
Filed
by a Party other than the Registrant ¨
|
|
Check
the appropriate box:
|
¨
|
Preliminary
Proxy Statement
|
¨
|
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
¨
|
Definitive
Proxy Statement
|
x
|
Definitive
Additional Materials
|
¨
|
Soliciting
Material under §240.14a-12
|
|
Zynerba
Pharmaceuticals, Inc.
|
(Name
of Registrant as Specified In Its Charter)
|
|
Not
Applicable
|
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
|
|
Payment
of Filing Fee (Check the appropriate box):
|
x
|
No
fee required.
|
¨
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title
of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
|
|
|
(5)
|
Total
fee paid:
|
|
|
|
¨
|
Fee
paid previously with preliminary materials.
|
¨
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date
of its filing.
|
|
(1)
|
Amount
Previously Paid:
|
|
|
|
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
|
|
|
|
(3)
|
Filing
Party:
|
|
|
|
|
(4)
|
Date
Filed:
|
|
|
|
|
|
|
|
SUPPLEMENT TO
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD JUNE 10, 2020
This supplement (the “Supplement”)
provides updated information with respect to the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of Zynerba
Pharmaceuticals, Inc. (“Zynerba”) to be held on June 10, 2020.
The following news release issued on May
21, 2020 supplements the Notice of the Annual Meeting and Definitive Proxy Statement of Zynerba furnished to stockholders and
filed with the Securities and Exchange Commission (“SEC”) on April 23, 2020 (the “Notice and Proxy Statement”).
The news release describes a change in the location of the Annual Meeting from an in-person to a virtual-only meeting and
should be read in conjunction with the Notice and Proxy Statement.
Except as specifically revised by the
information contained herein, this Supplement does not revise or update any of the other information set forth in the Notice and
Proxy Statement.
This Supplement is being filed with the
SEC and made available to shareholders at the Company’s website at www.zynerba.com.
THE NOTICE SHOULD BE READ IN CONJUNCTION
WITH THE PROXY STATEMENT
Zynerba Pharmaceuticals
Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic
DEVON, Pa., May 21, 2020 – Zynerba
Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for
rare and near-rare neuropsychiatric disorders, today announced that due to public health guidance related to the coronavirus (COVID-19)
pandemic and for the safety of participants its Annual Meeting has been changed to a virtual format only.
As previously announced, the Annual Meeting
will be held on June 10, 2020 at 8:00 a.m. Eastern Time for shareholders of record as of the close of business on April 14, 2020.
However, participants will not be able to attend the Annual Meeting in person. Both stockholders of record and street name stockholders
will need to register in advance by following the instructions below in order to be able to attend the Annual Meeting via live
audio webcast, submit their questions during the meeting and vote their shares electronically at the Annual Meeting.
Instructions for Participating in the Annual Meeting
In order to participate in the 2020 Annual
Meeting via live audio webcast, you must register at www.viewproxy.com/zynerbapharm/2020 by 11:59 p.m. Eastern Time on June 7,
2020. If you are a registered holder, you must register using your name, address and phone number as it appears on your Notice
of Internet Availability of Proxy Materials or your proxy card (if you received a printed copy of the proxy materials). A Virtual
Control Number will be assigned to you in a confirmation email following your registration.
If you hold your shares beneficially through
a bank or broker, you must provide a legal proxy from your bank or broker during registration and you will be assigned a Virtual
Control Number in order to vote your shares during the 2020 Annual Meeting. If you are unable to obtain a legal proxy to vote
your shares, you will still be able to attend the 2020 Annual Meeting (but will not be able to vote your shares) so long as you
demonstrate proof of stock ownership. Further instructions on how to attend the Annual Meeting via the internet, including how
to demonstrate proof of stock ownership and how to vote your shares electronically at the Annual Meeting are posted on www.viewproxy.com/zynerbapharm/2020
under Frequently Asked Questions (FAQ).
The Annual Meeting live audio webcast
will begin promptly at 8:00 a.m. Eastern Time on June 10, 2020. We encourage you to access the meeting prior to the start time.
Online check-in will begin at 7:30 a.m. Eastern Time and you should allow ample time for the check-in procedures. We will have
technicians available to assist you with access to the Annual Meeting. If you encounter difficulties accessing the Annual Meeting
live audio webcast during the check-in or meeting time, please email VirtualMeeting@viewproxy.com or call 1-866-612-8937.
Voting Methods
Whether or not shareholders plan to access
the Annual Meeting electronically, the Company encourages you to vote in advance of the Annual Meeting by using one of the methods
set forth in the proxy materials previously distributed, so that your vote will be counted even if you later decide not to attend
the virtual Annual Meeting. Shareholders who have already voted do not need to take any further voting action unless they wish
to change their vote.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in pharmaceutically-produced
transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of
patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder,
22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.
Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,”
“will,” “should” or other words that convey uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause
actual events or results to differ materially from the Company’s current expectations. These and other risks are described
in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current
reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any
forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company
assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise,
after the date of this press release.
Investor Contact
William Roberts, Vice President, Investor Relations and Corporate
Communications
Zynerba Pharmaceuticals
484.581.7489
robertsw@zynerba.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2023 to Mar 2024